This proposal represents a close collaborative effort between the Jardetzky and Longnecker laboratories to focus our understanding of Epstein-Barr virus (EBV) entry into target cells on potential therapeutic intervention. The entry of EBV into both epithelial cells and B cells is directly relevant to the Program Announcement for AIDS-related malignancies. Both cell types are EBV target tissues in the human host and the presence of EBV has been linked to cancerous growth in both tissues, in particular after the development of AIDS. The development of inhibitors of EBV entry into B cells and epithelial cells may prevent virus spread to susceptible cells inAIDS patients - while the linkage between EBVandAIDS-associated cancers is strong, not all EBV infected tissues become cancerous in AIDS patients, suggesting that infection of the right tissue at the right time may be important to disease development. We anticipate that a better understanding of EBV entry will be important for the development of therapeutics to treat EBV associated disease in AIDS patients and we are directly pursuing this goal by validating targets for inhibitor development, using both structural and functional approaches. Discoveries related to the proposed work will also be relevant to a general understanding of herpesvirus entry and replication and provide new tools to analyze key steps in herpesvirus penetration of cells. We feel that developing the tools to predict and validate protein:protein interaction inhibitors will become of increasing importance for both drug discovery and novel chemical biology approaches directed towards understanding fundamental mechanisms in biology. Our overall hypothesis is that there are multiple steps in the process of EBV entry into cells that are good targets for inhibitor development, such as the interactions of the EBV envelope glycoproteins that are critical to activating viral and cellular membrane fusion. The focus of this proposal is to develop lead inhibitors for known interaction sites in the EBV gp42 and gH/gL proteins that will block membrane fusion in B cells and to establish targets for inhibitor development in the gH/gL complex as a means to inhibiting both B cell and epithelial cell entry. Small molecule and peptide inhibitors of EBV entry will establish a basis for further development of antiviral drugs for the treatment of EBV infection and related diseases. The proposed combination of biophysical and structural methods with cell-based infection and celhcell fusion assays provides a comprehensive approach to the identification of therapeutic targets and lead compounds for the treatment of EBV-associated malignancies in patients with AIDS.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA117794-06
Application #
7778934
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Daschner, Phillip J
Project Start
2006-05-26
Project End
2011-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
6
Fiscal Year
2010
Total Cost
$262,636
Indirect Cost
Name
Stanford University
Department
Biology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Sathiyamoorthy, Karthik; Jiang, Jiansen; Möhl, Britta S et al. (2017) Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies. Proc Natl Acad Sci U S A 114:E8703-E8710
Sathiyamoorthy, Karthik; Hu, Yao Xiong; Möhl, Britta S et al. (2016) Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins. Nat Commun 7:13557
Chen, Jia; Jardetzky, Theodore S; Longnecker, Richard (2016) The Cytoplasmic Tail Domain of Epstein-Barr Virus gH Regulates Membrane Fusion Activity through Altering gH Binding to gp42 and Epithelial Cell Attachment. MBio 7:
Möhl, Britta S; Schröter, Christina; Klupp, Barbara G et al. (2016) Comparative Mutagenesis of Pseudorabies Virus and Epstein-Barr Virus gH Identifies a Structural Determinant within Domain III of gH Required for Surface Expression and Entry Function. J Virol 90:2285-93
Möhl, Britta S; Chen, Jia; Sathiyamoorthy, Karthik et al. (2016) Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus. Mol Cells 39:286-91
Rowe, Cynthia L; Chen, Jia; Jardetzky, Theodore S et al. (2015) Membrane anchoring of Epstein-Barr virus gp42 inhibits fusion with B cells even with increased flexibility allowed by engineered spacers. MBio 6:
Fan, Qing; Longnecker, Richard; Connolly, Sarah A (2014) Substitution of herpes simplex virus 1 entry glycoproteins with those of saimiriine herpesvirus 1 reveals a gD-gH/gL functional interaction and a region within the gD profusion domain that is critical for fusion. J Virol 88:6470-82
Sathiyamoorthy, Karthik; Jiang, Jiansen; Hu, Yao Xiong et al. (2014) Assembly and architecture of the EBV B cell entry triggering complex. PLoS Pathog 10:e1004309
Chen, Jia; Zhang, Xianming; Jardetzky, Theodore S et al. (2014) The Epstein-Barr virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion. J Virol 88:11686-95
Möhl, Britta S; Sathiyamoorthy, Karthik; Jardetzky, Theodore S et al. (2014) The conserved disulfide bond within domain II of Epstein-Barr virus gH has divergent roles in membrane fusion with epithelial cells and B cells. J Virol 88:13570-9

Showing the most recent 10 out of 36 publications